| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 46, 2015-2022, September 2005
Copyright © 2005 by American Society for Biochemistry and Molecular Biology
Methods |
* Department of Advanced Medical Technology and Development, BML, Inc., Saitama, Japan
Division of Internal Medicine, Hokkaido Hospital for Social Health Insurance, Sapporo, Japan
Institute of Medical Science, Health Sciences University of Hokkaido, Sapporo, Japan
** Cardiovascular Genetics Division, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT
Published, JLR Papers in Press, June 16, 2005. DOI 10.1194/jlr.D500018-JLR200
1 To whom correspondence should be addressed. e-mail: hhiro{at}bml.co.jp
Apolipoprotein A-V (apoA-V) is a recently discovered apolipoprotein that appears to have a role in plasma triglyceride (TG) transport. We have developed an ELISA for apoA-V using monoclonal antibodies that has a lower limit of detection of 0.3 ng/ml and linearity up to 20 ng/ml. The ELISA was then used to quantify plasma apoA-V in 196 healthy subjects and 106 patients with insulin-resistant diabetes mellitus. In the healthy subjects, total apoA-V concentration was 179.2 ± 74.8 ng/ml, and it was greater in females than in males (P < 0.005). It was correlated positively with the plasma HDL cholesterol (r = 0.32, P < 0.0001), apoA-I (r = 0.27, P = 0.0001), and apoE (r = 0.18, P = 0.011) concentrations and negatively with plasma TG concentration (r = –0.22, P = 0.021). In relation to single nucleotide polymorphism 3 (–1131C/T) of the apoA-V gene, apoA-V concentration was higher in the T/T type than in the C/C type (P < 0.01). Plasma TG concentration was lower in the T/T type than in the C/C or C/T type (P < 0.05).
ApoA-V concentration was lower in the diabetic patients (69.4 ± 44.3 ng/ml; P < 0.01) than in the healthy controls.
Abbreviations: apoA-V, apolipoprotein A-V; CBB, Coomassie brilliant blue; MAb, monoclonal antibody; NIDDM, non-insulin-dependent diabetes mellitus; rhapoA-V, recombinant human apolipoprotein A-V; SNP, single nucleotide polymorphism; SREBP-1c, sterol-regulatory element binding protein 1c; TG, triglyceride
Supplementary key words triglyceride • diabetes mellitus • immunoassay • single nucleotide polymorphism
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. R. Pullinger, B. E. Aouizerat, I. Movsesyan, V. Durlach, E. J. Sijbrands, K. Nakajima, A. Poon, G. M. Dallinga-Thie, H. Hattori, L. L. Green, et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients J. Lipid Res., August 1, 2008; 49(8): 1846 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Nelbach, X. Shu, R. J. Konrad, R. O. Ryan, and T. M. Forte Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice J. Lipid Res., March 1, 2008; 49(3): 572 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Moreno-Luna, F. Perez-Jimenez, C. Marin, P. Perez-Martinez, P. Gomez, Y. Jimenez-Gomez, J. Delgado-Lista, J. A. Moreno, T. Tanaka, J. M. Ordovas, et al. Two Independent Apolipoprotein A5 Haplotypes Modulate Postprandial Lipoprotein Metabolism in a Healthy Caucasian Population J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2280 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Q. Lai, D. K. Arnett, D. Corella, R. J. Straka, M. Y. Tsai, J. M. Peacock, X. Adiconis, L. D. Parnell, J. E. Hixson, M. A. Province, et al. Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants: The GOLDN Study Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1417 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Beckstead, K. Wong, V. Gupta, C.-P. L. Wan, V. R. Cook, R. B. Weinberg, P. M. M. Weers, and R. O. Ryan The C Terminus of Apolipoprotein A-V Modulates Lipid-binding Activity J. Biol. Chem., May 25, 2007; 282(21): 15484 - 15489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Schaap, M. C. Nierman, J. F. P. Berbee, H. Hattori, P. J. Talmud, S. F. C. Vaessen, P. C. N. Rensen, R. A. F. M. Chamuleau, J. A. Kuivenhoven, and A. K. Groen Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia J. Lipid Res., October 1, 2006; 47(10): 2333 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. C. Vaessen, F. G. Schaap, J.-A. Kuivenhoven, A. K. Groen, B. A. Hutten, S. M. Boekholdt, H. Hattori, M. S. Sandhu, S. A. Bingham, R. Luben, et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study J. Lipid Res., September 1, 2006; 47(9): 2064 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Alborn, M. G. Johnson, M. J. Prince, and R. J. Konrad Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein a5 in human serum. Clin. Chem., March 1, 2006; 52(3): 514 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Chan, G. F. Watts, M. N. Nguyen, and P. H. R. Barrett Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 590 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C.N. Rensen, K. W. van Dijk, and L. M. Havekes Apolipoprotein AV: Low Concentration, High Impact Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2445 - 2447. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
